Latest news

We are excited to announce that registrations are now open for the PVRI Drug Discovery and Development Symposium 2025! #DDDS2025 will be taking place 16-17 June 2025 in Amsterdam and promises to be an excellent opportunity for regulatory, industry, and academic bodies to meet and discuss the latest drug developments in PH.

On 27 September 2024, phase 1 of the Pulmonary Hypertension Global Patient Survey (PH GPS) closed. The survey was first launched in October 2023 to help clinicians better understand the impacts of PH on patients.

This World Heart Day, PVRI supports the WHF campaign calling for increased awareness, better healthcare policies and more funding for heart health research. 

The PVRI launched the Pulmonary Hypertension Global Patient Survey (PH GPS) in October 2023 to help clinicians better understand the impacts of PH on patients. The first global survey of its kind was aimed at those living with PH and their carers. 

The Aristotle Classes on PH & ACHD is a scientific event organised jointly by the Medical School of Aristotle University, Thessaloniki, Greece, the Heart Center at the University of Cologne, Germany and Royal Brompton & Harefield Hospitals, Imperial College, London, UK.

Congratulations to Joseph Newman, who was presented with the ELF Travel grant 10 September at the ERS Congress in Vienna for the best abstract in patient centred research entitled 'The Pulmonary Hypertension Global Patient Survey (PH GPS): an overview and results'. 

The submission deadline for submitting PVRI 2025 Rio abstracts has been extended! The best abstracts will be considered for travel awards. All accepted abstracts will be published in our journal, Pulmonary Circulation, and may appear on our website. 

The PVRI Innovative Drug Development Initiative (IDDI) Access to Care Workstream created the Access to Care poster which was presented at the PHA Conference in Indianapolis (15-18 August, 2024).

The purpose of the the Pulmonary Hypertension Association’s award is to support research aimed at addressing early diagnosis, education, and improving clinical outcomes and treatments for pulmonary hypertension (PH) patients who may be impacted by health inequities. Awards may be approved for up to a two (2) year period, up to $50,000/year.